PMID- 33600004
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 48
IP  - 5
DP  - 2021 May
TI  - Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer 
      caused by the combination of BRAF and MEK inhibitors in a patient with 
      BRAF-mutant melanoma.
PG  - 707-709
LID - 10.1111/1346-8138.15813 [doi]
AB  - The combination of BRAF inhibitor and MEK inhibitor is one of the first-line 
      treatments for unresectable BRAF-mutant melanoma or as an adjuvant therapy. 
      However, some patients who received the combination of dabrafenib and trametinib 
      (CombiDT) or the combination of encorafenib and binimetinib (CombiEB) had adverse 
      events (AEs) including pyrexia. We herein report a patient with BRAF-mutated 
      melanoma who repeatedly developed elevated levels of D-dimer and pyrexia after 
      CombiDT and CombiEB treatments. Moreover, concomitant edoxaban prevented these 
      AEs, enabling the patient to continue receiving CombiEB.
CI  - (c) 2021 Japanese Dermatological Association.
FAU - Mukai, Kei
AU  - Mukai K
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Kamata, Masahiro
AU  - Kamata M
AUID- ORCID: 0000-0003-0976-4982
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Miyazaki, Mirei
AU  - Miyazaki M
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Nagata, Mayumi
AU  - Nagata M
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Fukaya, Saki
AU  - Fukaya S
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Hayashi, Kotaro
AU  - Hayashi K
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Fukuyasu, Atsuko
AU  - Fukuyasu A
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Ishikawa, Takeko
AU  - Ishikawa T
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Ohnishi, Takamitsu
AU  - Ohnishi T
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Tada, Yayoi
AU  - Tada Y
AUID- ORCID: 0000-0003-3743-135X
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Tanaka, Takamitsu
AU  - Tanaka T
AD  - Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210218
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Pyridones)
RN  - 0 (Sulfonamides)
RN  - 0 (Thiazoles)
RN  - 0 (fibrin fragment D)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
RN  - NDU3J18APO (edoxaban)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Fever/chemically induced
MH  - Fibrin Fibrinogen Degradation Products
MH  - Humans
MH  - *Melanoma/drug therapy/genetics
MH  - Mitogen-Activated Protein Kinase Kinases
MH  - Mutation
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Pyridines
MH  - Pyridones/adverse effects
MH  - *Skin Neoplasms/drug therapy/genetics
MH  - Sulfonamides/therapeutic use
MH  - Thiazoles
OTO - NOTNLM
OT  - BRAF
OT  - D-dimer
OT  - MEK
OT  - anti-coagulant
OT  - edoxaban
OT  - malignant melanoma
EDAT- 2021/02/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/02/18 12:18
PHST- 2020/07/28 00:00 [received]
PHST- 2021/01/28 00:00 [accepted]
PHST- 2021/02/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/02/18 12:18 [entrez]
AID - 10.1111/1346-8138.15813 [doi]
PST - ppublish
SO  - J Dermatol. 2021 May;48(5):707-709. doi: 10.1111/1346-8138.15813. Epub 2021 Feb 
      18.